Sponsored

Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.

Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.

Researcher and clinician, Dr. Thomas Hutson reflects on the modern patient journey and shares his experience treating people with advanced RCC. Through the years, the advanced RCC treatment landscape has evolved significantly. In this two-part series brought to you by Eisai Inc., hear from oncologist Thomas Hutson, DO as he reflects on best practices for evaluating today’s treatment options.

The biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.

Pancreatic cancer remains elusive with extremely low survival rates. Through better utilization of existing therapies and identifying patient subgroups, some believe we are incrementally improving patient outcomes and making more significant advances in care.

Sponsored content by AbbVie

Sponsored Content by AstraZeneca

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Adaptive Biotechnologies OncLive Sponsored Content Q&A